B. Kurbanov

Proapoptotic Strategies against Melanoma Cells

G. Thieme, V. Stuttgart, J. Eberle, 2006 .

Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.

J. Eberle, U. Trefzer, L. Fecker, 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma

H. Fechner, J. Eberle, L. Fecker, 2007, Experimental dermatology.

Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4

J. Eberle, W. Sterry, L. Fecker, 2007, Oncogene.

Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

J. Eberle, C. Orfanos, L. Fecker, 2005, The Journal of investigative dermatology.

Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.

H. Fechner, J. Eberle, E. Stockfleth, 2011, Human gene therapy.